← All trials
NCT04882293
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Sep 30, 2021
- Completion date
- Jan 31, 2022
- First posted
- May 11, 2021
- Last posted
- Jun 10, 2021
- Enrollment
- 78
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Laboratorios Silanes S.A. de C.V.Lead sponsor
- Hospital Hispano S.A de C.VOverall official - principal investigator
- Instituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo y Enfermedades MetabolicasOverall official - principal investigator
- Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. (BIOMED-GDL)Overall official - principal investigator
- Resultados médicos, desarrollo e investigación SC (REMEDI)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.